SULFADOXINE, 250mg / PYRIMETHAMINE, 12.5mg, disp. tab.

STD DORASULP2TD

Valid Article


Article is intended to be used with children (<12 years) ONLY.
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
P01BD51
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.

OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

https://www.unicat.msf.org/web/image/product.template/574435/image_1920?unique=6e56d98

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

SULFADOXINE / PYRIMETHAMINE (SP) children

Therapeutic Action

Fixed-dose combination (FDC) of two antimalarials

Indications

Perennial Malaria Chemoprevention - PMC (formerly called SP-IPTi) in children under 24 months of age, in areas with moderate-to-high Plasmodium falciparum malaria transmission in countries in Sub-Saharan Africa.

Instructions for use

Resistance to sulfadoxine/pyrimethamine is becoming more and more frequent.

WHO recommends the co-administration of SP-IPTi with DTP2/Penta2, DTP3/Penta3 and measles immunization to infants, through routine EPI.

Precautions for Use

Do not use in combination with co-trimoxazole.

The dosage Sulfadoxine 500mg / Pyrimethamine 25mg is reserved to the Intermittent Preventive Treatment of malaria in Pregnant women (SP-IPTp).

Storage

Below 25°C ‐ Protect from sunlight